Pershing Square Foundation

Pershing Square Foundation describes itself as deploying "risk capital for philanthropy" — a framing borrowed directly from venture investing. The foundation was built on the fortune of hedge fund manager William A. Ackman and is now led by President Olivia Tournay Flatto (compensated at $393K in 2024). Trustee Neri Oxman — materials scientist and MIT Media Lab alumna — reflects the foundation's bias toward science-meets-design thinking. Together, they make concentrated, high-conviction bets on innovative leaders rather than spreading thin across many organizations.

For the vast majority of grant seekers, the hardest truth is this: the foundation does not accept unsolicited proposals in education, arts, economic development, social justice, or general health. These areas are invitation-only. The foundation's staff identifies organizations based on strategic fit and relationship, not RFP responses. Measures for Justice ($3M general support), the Innocence Project ($1M), and the Vera Institute ($500K) all received funding through relationship-driven selection, not open competition.

The only public application pathways are the foundation's three annual prize programs for academic researchers: - Pershing Square Sohn Cancer Prize — early-career oncology researchers at any US nonprofit institution - MIND Prize — early-career neuroscientists focused on Alzheimer's/Dementias - Lotus Award — scientists working on ovarian cancer research

All three follow the same architecture: $250,000/year for three years ($750,000 total), awarded to a minimum of six scientists per cycle. The multi-year structure is intentional — the foundation wants to underwrite bold, risky work at the stage when traditional NIH funding is scarce.

First-time applicants to prize programs should understand that the foundation values paradigm-challenging research over incremental work. Grant application language should lead with what makes the approach unconventional. Finalists are invited to present in New York City each March, so geographic accessibility matters operationally. The application portal (smapply.io) opens annually in late summer/early fall, with LOI deadlines typically in September–November.

Pershing Square Foundation's grantmaking has grown substantially as its asset base expanded from $94.6M in 2020 to $414.6M in 2024. Annual giving has stabilized in the $21M–$33M range after the anomalous 2021 ($66.4M) driven by extraordinary investment returns. The 2023 990 shows $32.8M in total giving with $21.2M in grants paid — the gap reflects timing differences in multi-year pledge disbursements.

Analyzing the 150 grants in the foundation's grantee record ($51.6M total), the median grant is $112,500 with an average of $343,884 — the latter pulled upward by several very large commitments. The range spans from $3,200 (smallest) to $8,000,000 (emergency assistance via Fidelity DAF). Most prize awards cluster at the $750,000 total ($250K × 3 years) commitment level.

By focus area (estimated from grantee data): - Biomedical research (cancer + neuroscience): ~$13.4M across 80+ grants — the dominant category, anchored by Memorial Sloan Kettering ($3.77M, 25 grants), Yale ($2.61M), and the Rockefeller University ($2.23M) - Immigrant opportunity and humanitarian aid: ~$8M — Robin Hood Foundation ($6.3M for the PSF Immigrant Opportunity Fund), Global Impact ($1.3M for war zone medical supplies) - Education and global leadership: ~$7.5M — University of Oxford ($6.9M for the Pershing Square Global Leadership Centre), Harvard ($600K for rowing program) - Social/criminal justice: ~$4.5M — Measures for Justice ($3M general support), Innocence Project ($1M), Vera Institute ($500K) - Arts and culture: ~$1.2M — Signature Theatre ($1M capital), Silk Road Project ($150K) - Environment and biotech: ~$650K — Revive & Restore ($500K), Greenwave ($150K)

Geography: 90 of 150 identified grants (60%) went to New York-based organizations. Massachusetts and Connecticut follow with 16 and 14 grants respectively, reflecting the elite university corridor. DC (3), Illinois (3), New Jersey (4), Maryland (4), California (4), Pennsylvania (3), and Washington (2) round out the footprint. Organizations outside the Northeast should not expect geographic advantage.

The Pershing Square Foundation occupies a distinctive position among foundations of similar asset scale — large enough to fund multimillion-dollar initiatives but operated with a focused, high-conviction strategy uncommon among peers in the Community Development NTEE category.

Among these peers, Pershing Square is the most transparent about its programs and the only one with publicly documented competitive prize programs open to outside applicants. Warren Alpert Foundation is the closest structural analog — similarly asset-rich, medical research-focused, and invitation-driven — but lacks the standardized prize architecture.

Pershing Square's competitive advantage is its willingness to fund early-career researchers before they have established track records, filling a genuine gap that NIH study sections routinely overlook. The 1–8 year post-independence requirement for prize eligibility is intentionally designed to catch researchers at peak creative risk-taking before funding conservatism sets in. No peer in this comparison group has articulated a comparable theory of change.

The most significant recent development is the Lotus Award launch in January 2026 — a rebranding and formalization of the one-time $5.25M Ovarian Cancer Challenge Grant (May 2025) into an annual competitive program. This signals the foundation is now running three parallel prize programs with identical financial architecture, representing a combined minimum commitment of $13.5M per year in research prizes alone.

In September 2025, the foundation expanded the Pershing Square Sohn Cancer Prize to all US institutions, removing the previous preference for researchers affiliated with the Sohn Conference network. This is a meaningful access shift — prior cycles disproportionately benefited NY metro researchers who had existing relationships with the Sohn ecosystem.

The 2026 MIND Prize opened in August 2025 with its LOI deadline of September 29, 2025. Since the prize launched in 2023, 20 investigators from across the country have been funded, including researchers at Rockefeller University, Broad Institute, MIT, Johns Hopkins, Cold Spring Harbor Laboratory, and UCLA.

On the leadership front, Olivia Tournay Flatto has served as President since at least 2018, with compensation rising from $345,000 (2021) to $392,723 (2023), reflecting institutional stability. William Ackman remains a trustee but is increasingly focused on his broader public profile and the planned IPO of Pershing Square Capital Management, which may affect philanthropic flows over time. Neri Oxman, formerly of MIT Media Lab, joined as trustee and has shaped the foundation's interest in materials science and biodesign.

For prize program applicants (Cancer Prize, MIND Prize, Lotus Award):

• Timing is everything. Applications open in late summer (MIND Prize: ~August; Cancer Prize: ~September; Lotus: ~December–January). Monitor the foundation's news page and smapply.io portal closely. There is no early notice system — announcements appear on the website and via press release.

• Apply to only one prize per cycle. The foundation explicitly bars applicants from submitting to multiple programs in the same year. Choose the one most aligned with your primary research focus. Attempting to straddle multiple programs suggests lack of focus and will disqualify you.

• Frame your research as paradigm-breaking, not incremental. The foundation's stated criterion is work that "rethinks conventional paradigms" and "defies conventional categorization." This is not boilerplate — reviewers actively screen for unconventional thinking. Lead with the surprising or counterintuitive aspect of your approach. Describe what dominant consensus you are challenging, not merely what gap you fill.

• Eligibility window is narrow. For both Cancer and MIND prizes: 1–8 years of independent laboratory experience by the award start date. Early-career means post-PI appointment, not post-PhD. Confirm your start date carefully; being outside this window is disqualifying.

• Prepare for in-person finals in New York City. Finalist presentations are scheduled for March each year. Budget for travel and plan your calendar accordingly.

• Current grantees: know your re-application window. You cannot apply to a second prize program until your award reaches its third year. Track your award milestones and apply early in the eligible window.

For non-prize areas (education, arts, social justice, economic development):

• Do not submit unsolicited proposals. The foundation is explicit that it does not accept them. A cold letter will not result in funding and may signal unfamiliarity with the foundation.

• Invest in relationship-building over time. Attend Philanthropy New York events where foundation staff participate. Engage with the Sohn Conference ecosystem if in oncology or health. Demonstrate impact in your sector that naturally surfaces you to the foundation's radar.

• Align your language with 'risk capital' and 'innovation.' When you do have an opportunity to speak with foundation staff, frame your organization's work as high-leverage, high-risk-for-high-reward — matching the foundation's self-described philosophy.